Everolimus	B:C0541315
for	O
Treatment	O
of	O
Pseudomyogenic	O
Hemangioendothelioma	I:C0018915
.	O

Everolimus	O
for	O
Treatment	B:C0087111
of	O
Pseudomyogenic	O
Hemangioendothelioma	I:C0018915
.	O

Everolimus	O
for	O
Treatment	O
of	O
Pseudomyogenic	B:C0018915
Hemangioendothelioma	I:C0018915
.	O

Pseudomyogenic	B:C0018915
hemangioendothelioma	I:C0018915
(	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
)	O
is	O
a	O
recently	O
described	O
vascular	O
neoplasm	I:C0282607
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	O
tissue	I:C0225317
of	O
the	O
distal	O
extremities	O
of	O
young	O
adults	O
.	O

Pseudomyogenic	O
hemangioendothelioma	I:C0018915
(	O
Pseudomyogenic	B:C0018915
hemangioendothelioma	I:C0018915
)	O
is	O
a	O
recently	O
described	O
vascular	O
neoplasm	I:C0282607
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	O
tissue	I:C0225317
of	O
the	O
distal	O
extremities	O
of	O
young	O
adults	O
.	O

Pseudomyogenic	O
hemangioendothelioma	I:C0018915
(	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
)	O
is	O
a	O
recently	O
described	O
vascular	B:C0282607
neoplasm	I:C0282607
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	O
tissue	I:C0225317
of	O
the	O
distal	O
extremities	O
of	O
young	O
adults	O
.	O

Pseudomyogenic	O
hemangioendothelioma	I:C0018915
(	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
)	O
is	O
a	O
recently	O
described	O
vascular	O
neoplasm	I:C0282607
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	B:C0225317
tissue	I:C0225317
of	O
the	O
distal	O
extremities	O
of	O
young	O
adults	O
.	O

Metastatic	O
Pseudomyogenic	B:C0018915
hemangioendothelioma	I:C0018915
can	O
be	O
fatal	O
and	O
there	O
are	O
no	O
effective	O
medications	O
.	O

Metastatic	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
can	O
be	O
fatal	O
and	O
there	O
are	O
no	O
effective	O
medications	B:C0013227
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
metastatic	O
Pseudomyogenic	B:C0018915
hemangioendothelioma	I:C0018915
,	O
who	O
responded	O
to	I:C0521982
treatment	I:C0521982
with	O
everolimus	O
,	O
a	O
mammalian	O
target	I:C2746052
of	I:C2746052
rapamycin	I:C2746052
inhibitor	I:C2746052
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
metastatic	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
,	O
who	O
responded	B:C0521982
to	I:C0521982
treatment	I:C0521982
with	O
everolimus	O
,	O
a	O
mammalian	O
target	I:C2746052
of	I:C2746052
rapamycin	I:C2746052
inhibitor	I:C2746052
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
metastatic	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
,	O
who	O
responded	O
to	I:C0521982
treatment	I:C0521982
with	O
everolimus	B:C0541315
,	O
a	O
mammalian	O
target	I:C2746052
of	I:C2746052
rapamycin	I:C2746052
inhibitor	I:C2746052
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
metastatic	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
,	O
who	O
responded	O
to	I:C0521982
treatment	I:C0521982
with	O
everolimus	O
,	O
a	O
mammalian	B:C2746052
target	I:C2746052
of	I:C2746052
rapamycin	I:C2746052
inhibitor	I:C2746052
.	O

Immunohistochemistry	B:C0021044
showed	O
that	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
biopsy	O
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
tumor	O
size	I:C0475440
following	O
treatment	O
.	O

Immunohistochemistry	O
showed	O
that	O
mammalian	B:C1307407
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
biopsy	O
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
tumor	O
size	I:C0475440
following	O
treatment	O
.	O

Immunohistochemistry	O
showed	O
that	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	B:C1171362
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
biopsy	O
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
tumor	O
size	I:C0475440
following	O
treatment	O
.	O

Immunohistochemistry	O
showed	O
that	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	O
in	O
Pseudomyogenic	B:C0018915
hemangioendothelioma	I:C0018915
biopsy	O
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
tumor	O
size	I:C0475440
following	O
treatment	O
.	O

Immunohistochemistry	O
showed	O
that	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
biopsy	B:C0677862
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
tumor	O
size	I:C0475440
following	O
treatment	O
.	O

Immunohistochemistry	O
showed	O
that	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
biopsy	O
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	B:C0018915
hemangioendothelioma	I:C0018915
tumor	O
size	I:C0475440
following	O
treatment	O
.	O

Immunohistochemistry	O
showed	O
that	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
biopsy	O
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
tumor	B:C0475440
size	I:C0475440
following	O
treatment	O
.	O

Immunohistochemistry	O
showed	O
that	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
was	O
expressed	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
biopsy	O
specimens	I:C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
Pseudomyogenic	O
hemangioendothelioma	I:C0018915
tumor	O
size	I:C0475440
following	O
treatment	B:C0087111
.	O

